SG Americas Securities’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-30,900
| Closed | -$602K | – | 2961 |
|
|
2025
Q1 | $602K | Sell |
30,900
-16,500
| -35% | -$2.36M | ﹤0.01% | 1616 |
|
|
2024
Q4 | $901K | Hold |
47,400
| – | – | ﹤0.01% | 912 |
|
|
2024
Q3 | $279K | Hold |
47,400
| – | – | ﹤0.01% | 2218 |
|
|
2024
Q2 | $227K | Buy |
47,400
+27,600
| +139% | +$6M | ﹤0.01% | 2109 |
|
|
2024
Q1 | $192K | Buy |
19,800
+7,900
| +66% | +$1.85M | ﹤0.01% | 2005 |
|
|
2023
Q4 | $22K | Hold |
11,900
| – | – | ﹤0.01% | 2997 |
|
|
2023
Q3 | $76K | Buy |
+11,900
| New | +$3.18M | ﹤0.01% | 2858 |
|
|
2022
Q4 | – | Sell |
-150,000
| Closed | -$84K | – | 3071 |
|
|
2022
Q3 | $84K | Buy |
150,000
+145,000
| +2,900% | +$30.8M | ﹤0.01% | 2896 |
|
|
2022
Q2 | $106K | Hold |
5,000
| – | – | ﹤0.01% | 3096 |
|
|
2022
Q1 | $125K | Sell |
5,000
-43,700
| -90% | -$9.5M | ﹤0.01% | 2676 |
|
|
2021
Q4 | $1.42M | Buy |
48,700
+13,600
| +39% | +$3.5M | 0.01% | 1369 |
|
|
2021
Q3 | $749K | Sell |
35,100
-16,900
| -33% | -$5.54M | ﹤0.01% | 2158 |
|
|
2021
Q2 | $880K | Buy |
52,000
+42,000
| +420% | +$12.7M | ﹤0.01% | 1646 |
|
|
2021
Q1 | $535K | Sell |
10,000
-42,000
| -81% | -$11.3M | ﹤0.01% | 1986 |
|
|
2020
Q4 | $2.79M | Hold |
52,000
| – | – | 0.01% | 864 |
|
|
2020
Q3 | $2.05M | Sell |
52,000
-6,000
| -10% | -$1.67M | 0.01% | 719 |
|
|
2020
Q2 | $2.89M | Sell |
58,000
-11,400
| -16% | -$3.43M | 0.02% | 607 |
|
|
2020
Q1 | $1.88M | Sell |
69,400
-114,700
| -62% | -$34.8M | 0.02% | 846 |
|
|
2019
Q4 | $1.93M | Sell |
184,100
-12,900
| -7% | -$3.58M | 0.02% | 843 |
|
|
2019
Q3 | $3.16M | Sell |
197,000
-21,700
| -10% | -$5.05M | 0.03% | 666 |
|
|
2019
Q2 | $6.24M | Sell |
218,700
-94,800
| -30% | -$21.9M | 0.04% | 434 |
|
|
2019
Q1 | $14.4M | Buy |
313,500
+34,100
| +12% | +$10.7M | 0.13% | 152 |
|
|
2018
Q4 | $6.16M | Buy |
279,400
+21,500
| +8% | +$6.86M | 0.05% | 321 |
|
|
2018
Q3 | $2.57M | Buy |
257,900
+94,200
| +58% | +$32.4M | 0.02% | 976 |
|
|
2018
Q2 | $3.63M | Sell |
163,700
-5,000
| -3% | -$1.41M | 0.03% | 581 |
|
|
2018
Q1 | $5.95M | Sell |
168,700
-143,600
| -46% | -$44.6M | 0.05% | 350 |
|
|
2017
Q4 | $2.86M | Buy |
312,300
+99,900
| +47% | +$32M | 0.03% | 663 |
|
|
2017
Q3 | $842K | Sell |
212,400
-11,100
| -5% | -$3.29M | 0.01% | 1393 |
|
|
2017
Q2 | $1.47M | Buy |
223,500
+119,600
| +115% | +$31.6M | 0.01% | 1122 |
|
|
2017
Q1 | $893K | Sell |
103,900
-83,900
| -45% | -$23.7M | 0.01% | 1452 |
|
|
2016
Q4 | $1.26M | Hold |
187,800
| – | – | 0.01% | 1165 |
|
|
2016
Q3 | $1.18M | Buy |
187,800
+58,500
| +45% | +$17.3M | 0.01% | 1056 |
|
|
2016
Q2 | $1.8M | Buy |
129,300
+32,500
| +34% | +$8.57M | 0.01% | 903 |
|
|
2016
Q1 | $1.39M | Sell |
96,800
-22,900
| -19% | -$6.05M | 0.01% | 1099 |
|
|
2015
Q4 | $1.23M | Buy |
+119,700
| New | +$34.4M | 0.01% | 1006 |
|
|
2015
Q3 | – | Sell |
-78,700
| Closed | -$1.47M | – | 2116 |
|
|
2015
Q2 | $1.47M | Buy |
78,700
+60,400
| +330% | +$24.2M | 0.01% | 857 |
|
|
2015
Q1 | $116K | Buy |
18,300
+6,000
| +49% | +$2.36M | ﹤0.01% | 2184 |
|
|
2014
Q4 | $147K | Buy |
+12,300
| New | +$3.98M | ﹤0.01% | 2657 |
|
Other funds holding BIIB
VCM
VPM
SG Americas Securities's BIIB Position: Q1 2026 in Review
SG Americas Securities increased its Biogen (BIIB) stake by 6.4% in Q1 2026, buying an estimated $2.18M and bringing the position to 195,668 shares worth $35.9M. The position accounts for 0.04% of the portfolio, ranked #364.
SG Americas Securities first reported a position in BIIB in Q2 2013 and has held it in 51 quarters since. The position peaked at $98.5M in Q1 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- SG Americas Securities held 195,668 shares of Biogen worth $35.9M as of Q1 2026.
- SG Americas Securities bought 11,839 Biogen shares in Q1 2026, an estimated $2.18M.
- Biogen made up 0.04% of SG Americas Securities's portfolio in Q1 2026, its #364 holding.
- SG Americas Securities first reported a position in Biogen in Q2 2013 and has held it in 51 quarters since.
- SG Americas Securities's Biogen position peaked at $98.5M in Q1 2025.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.